Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Zucker Hillside Hospital, Glen Oaks, New York, NY, USA (США) 2 Albert Einstein College of Medicine, Bronx, NY, USA (США) 3 Hofstra North Shore – LIJ School of Medicine, Hempstead, NY, USA (США) 4 University Psychiatric Centre KU Leuven, Campus Kortenberg, Kortenberg, Belgium (Бельгия) 5 Department of Psycho-oncology, Leicestershire Partnership NHS Trust, Leicester, UK (Великобритания) 6 Department of Cancer and Molecular Medicine, University of Leicester, Leicester, UK (Великобритания) 7 KU Leuven Department of Rehabilitation Sciences, Leuven, Belgium (Бельгия)
Список исп. литературыСкрыть список 1. Spelling B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76-102. 2. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. SchizophrBull 2013;39:1174-9. 3. Miller BJ, Buckley P, Seabolt W et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-71. 4. Miller BJ, Culpepper N, Rapaport MH et al. Prenatal inflammation and neuro-development in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry 2013;42: 92-100. 5. Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995;45:135-41. 6. Schwarz MJ, Muller N, Riedel M et al. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001;56:483-6. 7. Busse S, Busse M, Schlitz K et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patientswith residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun 2012;26:1273-9. 8. Nitta M, Kishimoto T, Muller N et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013;39:1230-41. 9. Sommer IE, van Westrhenen R, Begemann MJ et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014;40:181-91. 10. Keller WR, Kum LM, Wehring HJ et al. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013;27:337-42. 11. Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014;75: 292-9. 12. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill’s ‘guidelines for causation’ contribute? J R Soc Med 2009;102:186-94. 13. Arolt V, Weitzsch C, Wilke I et al. Production of interferongamma in families with multiple occurrence of schizophrenia. Psychiatry Res 1997;66:145-52. 14. Gaughran F, O’Neill E, Sham P et al. Soluble interleukin-2 receptor levels in families of people with schizophrenia. Schizophr Res 2002;56:2235-9. 15. Martinez-Gras I, Garcia-Sanchez F, Guaza C et al. Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res 2012;200:1022-5. 16. Dimitrov DH, Lee S, Yantis J et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res 2013;151:29-35. 17. Borovcanin M, Jovanovic I, Radosavljevic G et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation on the type-2 inflammatory response. Schizophr Res 2013;147:103-9. 18. Hope S, Ueland T, Steen NE et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013;145:36-42. 19. Ezeoke A, Mellor A, Buckley P et al. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res 2013;150:245-51. 20. Benros ME, Pedersen MG, Rasmussen H et al. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry (in press). 21. Howren MD, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-86. 22. Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014;48: 261-7. 23. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57. 24. Hiles SA, Baker AL, de Malmanche T et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 2012;42:2015-26. 25. Na KS, Lee KJ, Lee JS et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:79-85. 26. Serafini G, Pompili M, Elena-Serretti M et al. The role of inflammatory cytokines in suicidal beh * avior: a systematic review. Eur Neuropsychopharmacol 2013;23:1672-86. 27. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36:2452-9. 28. Maes M, Meltzer H, Jacobs J et al. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatr Scand 1993;87:160-6. 29. Horning M, Amsterdam JD, Kamoun M et al. Autoantibody disturbances in affective disorders: a function of age and gender? J Affect Disord 1999;55:29-37. 30. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:664-75. 31. Modabbernia A, Taslimi S, Brietzke E et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013;74:15-25. 32. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3:35-42. 33. Jernas M, Palming J, Sjoholm K et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 2006;20:1540-2. 34. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301. 35. Berg AH, Combs TP, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53. 36. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-Bank NF-xB. Nat Med 2005;11:183-90. 37. Hanssens L, van Winkel R, Wampers M et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008;106: 308-14. 38. Wampers M, Hanssens L, van Winkel R et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 2012;22:17-26. 39. Ouchi N, Parker JL, Lugus JJ et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97. 40. Wager-Smith K, Markou A. Depression: a repair response to stress induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev 2011;35:742-64. 41. Brydon L, Walker C, Wawrzyniak A et al. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 2004;18: 458-67. 42. Deinzer R, Granrath N, Stuhl H et al. Acute stress effects on local IL-1beta responses to pathogens in a human in vivo model. Brain Behav Immun 2004;18:458-67.